Taylor Woodson
Payments from drug & device makers
Across 115 payments — averaging $19.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$619
- AbbVie$246
- Lilly USA, LLC$220
- Boehringer Ingelheim$117
- Pfizer$97
- Novo Nordisk$88
- plus $839 from 21 others
What the payments were for
- Food & beverage$2,227100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 24 | $619 |
| AbbVie | 15 | $246 |
| Lilly USA, LLC | 12 | $220 |
| Boehringer Ingelheim | 7 | $117 |
| Pfizer | 6 | $97 |
| Novo Nordisk | 6 | $88 |
| Lundbeck LLC | 5 | $86 |
| Otsuka America Pharmaceutical, Inc. | 4 | $81 |
| GSK | 4 | $73 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $70 |
| Astellas Pharma US Inc | 4 | $58 |
| Eisai Inc. | 3 | $49 |
| CSL Behring | 2 | $48 |
| Phathom Pharmaceuticals, Inc. | 2 | $41 |
| Novartis | 2 | $41 |
| Sanofi-aventis U.S. LLC | 2 | $40 |
| Johnson & Johnson(2 entities) | 2 | $39 |
| Sumitomo Pharma America, Inc. | 1 | $29 |
| Amgen | 2 | $29 |
| Viatris Specialty LLC | 1 | $27 |
| Mylan Specialty L.p. | 1 | $26 |
| Scilex Pharmaceuticals Inc. | 1 | $21 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
| Exact Sciences | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Bayer | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$122
How this compares
$2,227 in reported general payments places this provider in the 80th percentile of 4,522 family providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 107 | $112,355 |
| MounjaroTirzepatide | 71 | $78,584 |
| JardianceEmpagliflozin | 74 | $60,174 |
| FarxigaDapagliflozin Propanediol | 76 | $60,169 |
| EliquisApixaban | 70 | $43,094 |
| LinzessLinaclotide | 76 | $41,828 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $35,322 |
| JanuviaSitagliptin Phosphate | 26 | $30,249 |
| VraylarCariprazine Hcl | 18 | $26,505 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $21,379 |
| RybelsusSemaglutide | 20 | $20,979 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $13,404 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $12,420 |
| MyrbetriqMirabegron | 25 | $11,679 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $8,842 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $88 | $133,335127 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $619 | $81,407127 claims |
| Lilly USA, LLCMounjaro | $220 | $78,58471 claims |
| AbbVieLinzess, Vraylar, Synthroid | $246 | $69,832108 claims |
| Boehringer IngelheimJardiance, Tradjenta | $117 | $65,72885 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $73 | $44,16466 claims |
| PfizerEliquis | $97 | $43,09470 claims |
| Astellas Pharma US IncMyrbetriq | $58 | $11,67925 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,522 family providers in North Carolina.
Other family in Eden
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
- Teresa DossWilmington$137K
- Debra ScottCharlotte$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.